Suven Pharma acquires Casper Pharma for Rs 155 Cr

The Board of Directors of Suven Pharmaceuticals Limited (SPL) has approved the investments by way of purchase of entire (100 per cent) share capital from the existing shareholders of Casper Pharma Private Limited (CPPL), a Hyderabad based SEZ company engaged in formulations business. Post purchase of shares, the target entity would become a wholly owned subsidiary of SPL. Cash consideration of $20.5 million based on the present exchange rate equivalent to around Rs 155 crore will be paid to the sellers of the shares in the target entity. The present manufacturing facility of Casper Pharma has an installed capacity of 1.2 billion tablets/ capsules. The company is ready for USFDA inspection which is expected to happen within the next 6 months’ time frame. The unit is yet to reach its commercially viable operations. The objective of this acquisition is to acquire formulations facility of Casper Pharma and to engage in manufacturing and supplying solid oral dosage formulations including tablets, capsules and liquid oral products through the contractual arrangement with customers for USA and other regulated markets.